About Evergreen Theragnostics
Evergreen Theragnostics is a Healthcare company based in Jersey City (United States) founded in 2019, and was acquired by Lantheus in January 2025. Radiopharmaceutical manufacturing and regulatory services are provided. Evergreen Theragnostics has raised $75.91 million across 4 funding rounds from investors including Lantheus, Liftt and Petrichor. Its chief executive, as recorded, is James Cook. Evergreen Theragnostics offers products and services including CDMO Products and Radiopharmaceuticals. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides. Its legal entity is Evergreen Theragnostics, Inc. Its competitors include Pfizer, LabConnect and Ainos; 2 of its 3 listed competitors have raised funding.
Company details
Evergreen Theragnostics was founded in 2019 and is based in Jersey City, United States. Operations are centered in the radiopharmaceutical sector, where manufacturing of specialized compounds for therapeutic and diagnostic uses is conducted. Regulatory services are offered to ensure compliance with industry standards. The company supports clients in developing and commercializing radiopharmaceutical products, with leadership directed by CEO James Cook. Focus remains on precision medicine applications within biotechnology.
- Headquarters Jersey City, United States
- Stage Acquired
- SectorsHealthcare
- Website evergreentgn.com
- Social LinkedIn
- Acquired by Lantheus (Jan 2025)
- Legal Name Evergreen Theragnostics, Inc.
Products & Services of Evergreen Theragnostics
Evergreen Theragnostics offers a comprehensive portfolio of products and services, including CDMO Products and Radiopharmaceuticals.
Contract development for therapeutic pipelines in healthcare
Products designed to enhance cancer patient options via theragnostics
Funding Insights of Evergreen Theragnostics
Evergreen Theragnostics has successfully raised a total of $75.91M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $26 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75.91M
- Total Rounds 4
- Last Round Series C — $26M
- First Round $19.45M
(Apr 2020)
- Investors Count 2
All 4 funding rounds of Evergreen Theragnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Evergreen Theragnostics
Evergreen Theragnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Lantheus, Liftt and Petrichor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Venture capital firm focused on multiple sectors | 2019 | liftt.com | Torino, Italy | |
Developer of diagnostic imaging agents and targeted therapeutics | 2008 | lantheus.com | Billerica, United States |
Investor details for Evergreen Theragnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evergreen Theragnostics
5 people are tracked at Evergreen Theragnostics (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
James Cook | CEO | Leadership |
Thomas Reiner | Chief Scientific Officer | Leadership |
Giacomo Pirovano | Director Of Discovery Strategy And Business Development | Leadership |
Dipesh Patel | General Manager & General Counsel | Leadership |
Stephanie Campi | Microbiology Manager | Team |
Complete people profiles for Evergreen Theragnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Evergreen Theragnostics
4 dated milestones of Evergreen Theragnostics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Evergreen Theragnostics is founded.
- Funding First funding round of $19.5M.
- Funding Latest funding round, Series C, of $26.0M.
- Exit Acquired by Lantheus.
Competitors of Evergreen Theragnostics
Evergreen Theragnostics has 3 listed competitors in our database, 2 of them funded. They include Pfizer, LabConnect and Ainos.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pfizer.com | 1849 | New York, United States | $8M | Pharmaceutical products for treating multiple diseases are provided. | ||
| labconnect.com | 2002 | Johnson, United States | $28.5M | Laboratory testing, clinical trial research, and biopharma services are provided. | ||
| ainos.com | 1986 | San Diego, United States | 43 | Novel point-of-care testing and low-dose interferon therapeutics are developed. |
Detailed competitors of Evergreen Theragnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evergreen Theragnostics
The website of Evergreen Theragnostics (evergreentgn.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▼ 7.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Evergreen Theragnostics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evergreen Theragnostics
Complete news archive for Evergreen Theragnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evergreen Theragnostics
Evergreen Theragnostics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Evergreen Theragnostics is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
James Cook is the CEO of Evergreen Theragnostics, as recorded in our data.
Evergreen Theragnostics is a funded company, having raised a total of $75.91M across 4 funding rounds to date. The company's 1st funding round was a Series A of $19.45M, raised on Apr 2020.
Evergreen Theragnostics was founded in 2019 and is based in Jersey City, United States. Operations are centered in the radiopharmaceutical sector, where manufacturing of specialized compounds for therapeutic and diagnostic uses is conducted. Regulatory services are offered to ensure compliance with industry standards. The company supports clients in developing and commercializing radiopharmaceutical products, with leadership directed by CEO James Cook. Focus remains on precision medicine applications within biotechnology.
Evergreen Theragnostics's top competitors include Pfizer, LabConnect and Ainos.
Evergreen Theragnostics offers CDMO Products and Radiopharmaceuticals.
Evergreen Theragnostics operates through Evergreen Theragnostics, Inc..
Yes. Evergreen Theragnostics was acquired by Lantheus in January 2025.